EP1234833A3 - Herstellung von kristalliner Dihydratform von Azithromycin - Google Patents

Herstellung von kristalliner Dihydratform von Azithromycin Download PDF

Info

Publication number: EP1234833A3
Authority: EP; European Patent Office
Prior art keywords: preparation; azithromycin dihydrate; crystalline azithromycin; crystalline; dsc
Prior art date: 1999-11-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

EP01204550A

Other languages

English (en)

French (fr)

Other versions

EP1234833B1 (de

EP1234833A2 (de

Inventor

Miguel Santos Bayod Jasanada

Isidro Llorente Garcia

Félix Fernandez Mari

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

AsturPharma SA

Original Assignee

AsturPharma SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-11-26

Filing date

2000-02-23

Publication date

2003-03-12

2000-02-23 Application filed by AsturPharma SA filed Critical AsturPharma SA

2002-08-28 Publication of EP1234833A2 publication Critical patent/EP1234833A2/de

2003-03-12 Publication of EP1234833A3 publication Critical patent/EP1234833A3/de

2006-05-10 Application granted granted Critical

2006-05-10 Publication of EP1234833B1 publication Critical patent/EP1234833B1/de

2020-02-23 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP01204550A 1999-11-26 2000-02-23 Herstellung von kristalliner Dihydratform von Azithromycin Expired - Lifetime EP1234833B1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ES9902620		1999-11-26
ES009902620A ES2177373B1 (es)	1999-11-26	1999-11-26	Preparacion de azitromicina en su forma no cristalina
EP00500028A EP1103558B1 (de)	1999-11-26	2000-02-23	Herstellung von nicht-kristallinen und kristallinen Dihydratformen von Azithromycin

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
EP00500028A Division EP1103558B1 (de)	1999-11-26	2000-02-23	Herstellung von nicht-kristallinen und kristallinen Dihydratformen von Azithromycin

Publications (3)

Publication Number	Publication Date
EP1234833A2 EP1234833A2 (de)	2002-08-28
EP1234833A3 true EP1234833A3 (de)	2003-03-12
EP1234833B1 EP1234833B1 (de)	2006-05-10

Family

ID=8310747

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
EP00500028A Expired - Lifetime EP1103558B1 (de)	1999-11-26	2000-02-23	Herstellung von nicht-kristallinen und kristallinen Dihydratformen von Azithromycin
EP01204550A Expired - Lifetime EP1234833B1 (de)	1999-11-26	2000-02-23	Herstellung von kristalliner Dihydratform von Azithromycin

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
EP00500028A Expired - Lifetime EP1103558B1 (de)	1999-11-26	2000-02-23	Herstellung von nicht-kristallinen und kristallinen Dihydratformen von Azithromycin

Country Status (9)

Country	Link
US (1)	US6451990B1 (de)
EP (2)	EP1103558B1 (de)
JP (2)	JP4260354B2 (de)
AT (2)	ATE325805T1 (de)
CA (1)	CA2326930C (de)
DE (2)	DE60003509T2 (de)
ES (2)	ES2177373B1 (de)
PL (1)	PL195910B1 (de)
TR (1)	TR200003474A3 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20020231A2 (en) *	2002-03-18	2003-12-31	Pliva D D	ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
CA2245398C (en)	1998-08-21	2002-01-29	Apotex Inc.	Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
ES2162764B1 (es) *	2000-05-17	2003-04-01	Ercros Ind Sa	Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion.
CA2429639C (en) *	2000-11-27	2009-07-14	Biochemie S.A.	Stable azithromycin monohydrate
IN190080B (de) *	2001-01-29	2003-06-07	Alembic Ltd
KR100491183B1 (ko) *	2001-03-21	2005-05-25	한미약품 주식회사	아지트로마이신의 제조방법 및 이 방법에 사용되는9-데옥소-9에이-아자-9에이-호모에리트로마이신 에이의결정성 수화물
EP1671979B1 (de) *	2001-05-22	2008-08-13	Pfizer Products Inc.	Neue Kristallforme von Azithromycin
IL158591A0 (en) *	2001-05-22	2004-05-12	Pfizer Prod Inc	Crystal forms of azithromycin
US6861413B2 (en)	2001-05-22	2005-03-01	Pfizer Inc.	Stable non-dihydrate azithromycin oral suspensions
IL161996A0 (en)	2001-12-21	2005-11-20	Pfizer Prod Inc	Directly compressible formulations of azithromycin
US7452692B2 (en)	2002-02-13	2008-11-18	Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság	Method for extracting a macrolide from biomatter
JP4261365B2 (ja)	2002-02-13	2009-04-30	テバジョジセルジャールザ−トケルエンムケドレ−スベニュタ−ルシャシャ−グ	生物学的物質からのマクロライドの抽出方法
HRP20020614A2 (en)	2002-07-22	2004-06-30	PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o.	Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
WO2004089958A2 (en) *	2003-03-31	2004-10-21	TEVA Gyógyszergyár Részvénytársaság	Crystallization and purification of macrolides
ATE378345T1 (de)	2003-07-24	2007-11-15	Teva Gyogyszergyar Zartkoeruee	Verfahren zur aufreinigung von makroliden
JP2007513145A (ja) *	2003-12-04	2007-05-24	ファイザー・プロダクツ・インク	医薬用多微粒子の製造方法
US7384921B2 (en) *	2004-02-20	2008-06-10	Enanta Pharmaceuticals, Inc.	Polymorphic forms of 6-11 bicyclic ketolide derivatives
US7468428B2 (en)	2004-03-17	2008-12-23	App Pharmaceuticals, Llc	Lyophilized azithromycin formulation
US20060116336A1 (en) *	2004-03-17	2006-06-01	American Pharmaceutical Partners, Inc.	Lyophilized azithromycin formulation
WO2006115494A1 (en) *	2005-04-26	2006-11-02	American Pharmaceutical Partners, Inc.	Lyophilized azithromycin formulation
US7683162B2 (en)	2004-08-30	2010-03-23	Taro Pharmaceutical Industries Limited	Process of preparing a crystalline azithromycin monohydrate
US7582312B2 (en) *	2004-11-15	2009-09-01	Discovery Laboratories, Inc.	Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) *	2004-12-10	2008-12-09	L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude	Simplified process simulator
CA2584358A1 (en)	2004-12-01	2006-06-08	Teva Gyogyszergyar Zartkoeruen Mukoedo Reszvenytarsasag	Non-hygroscopic and powdery amorphous pimecrolimus
CA2615080A1 (en) *	2005-07-14	2007-01-18	Pfizer Products Inc.	Process for forming amorphous azithromycin particles
RU2008120712A (ru) *	2005-12-07	2010-01-20	Вайет (Us)	Способы получения кристаллического рапамицина и определения кристалличности соединений рапамицина при помощи дифференциальной сканирующей калориметрии
UA102128C2 (en) *	2008-12-05	2013-06-10	Х. Луннбек А/С	Nalmefene hydrochloride dihydrate
WO2011015219A1 (en)	2009-08-06	2011-02-10	Shifa Pharmed Industrial Group Co.	Process for the purification of azithromycin by separation from its thermal degradation products and/or isomers
BR112012014926A2 (pt) *	2009-12-18	2015-09-15	Univ Northwest	composição compreendendo uma forma vítrea não cristalina e amorfa de azitromicina
WO2013088274A1 (en) *	2011-12-14	2013-06-20	Wockhardt Limited	Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
CN106188177A (zh) *	2016-07-12	2016-12-07	浙江亚太药业股份有限公司	一种阿奇霉素化合物的制备方法及其药物制剂
CN108003109A (zh) *	2017-12-18	2018-05-08	南开大学	一种大环内酯化合物的晶型及其制备方法与用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0827965A2 (de) *	1996-07-11	1998-03-11	Astur-Pharma, S.A.	Synthese von 9-Deoxo-9a-Aza 11,12-Deoxy-9a-Methyl-9a-Homoerythromycin A 11,12-hydrogenorthoborat-dihydrat
WO1999058541A2 (en) *	1998-05-08	1999-11-18	Biochemie S.A.	Improvements in macrolide production

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI8110592A8 (en) *	1981-03-06	1996-06-30	Pliva Pharm & Chem Works	Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en)	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RO107257B1 (ro)	1987-07-09	1993-10-30	Pfizer	Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
ES2104386T3 (es) *	1993-05-19	1997-10-01	Pfizer	Compuesto intermedio para la acitromicina.
ECSP951389A (es)	1995-02-21	1996-05-10		Un procedimiento de obtencion de hidrato de azitromicina
PT102130A (pt)	1998-03-13	1999-09-30	Hovione Sociedade Quimica S A	Processo de preparacao de dihidrato de azitromicina
CA2245398C (en) *	1998-08-21	2002-01-29	Apotex Inc.	Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof

1999
- 1999-11-26 ES ES009902620A patent/ES2177373B1/es not_active Expired - Fee Related
2000
- 2000-02-23 EP EP00500028A patent/EP1103558B1/de not_active Expired - Lifetime
- 2000-02-23 AT AT01204550T patent/ATE325805T1/de not_active IP Right Cessation
- 2000-02-23 AT AT00500028T patent/ATE243704T1/de not_active IP Right Cessation
- 2000-02-23 DE DE60003509T patent/DE60003509T2/de not_active Expired - Fee Related
- 2000-02-23 DE DE60027919T patent/DE60027919D1/de not_active Expired - Lifetime
- 2000-02-23 EP EP01204550A patent/EP1234833B1/de not_active Expired - Lifetime
- 2000-11-22 US US09/718,833 patent/US6451990B1/en not_active Expired - Fee Related
- 2000-11-23 TR TR2000/03474A patent/TR200003474A3/tr unknown
- 2000-11-24 CA CA002326930A patent/CA2326930C/en not_active Expired - Fee Related
- 2000-11-24 PL PL344101A patent/PL195910B1/pl not_active IP Right Cessation
- 2000-11-27 JP JP2000359948A patent/JP4260354B2/ja not_active Expired - Fee Related
2002
- 2002-10-09 ES ES200202318A patent/ES2207403B1/es not_active Expired - Fee Related
2008
- 2008-08-26 JP JP2008217072A patent/JP2009007376A/ja active Pending

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0827965A2 (de) *	1996-07-11	1998-03-11	Astur-Pharma, S.A.	Synthese von 9-Deoxo-9a-Aza 11,12-Deoxy-9a-Methyl-9a-Homoerythromycin A 11,12-hydrogenorthoborat-dihydrat
WO1999058541A2 (en) *	1998-05-08	1999-11-18	Biochemie S.A.	Improvements in macrolide production

Also Published As

Publication number	Publication date
ES2177373A1 (es)	2002-12-01
CA2326930A1 (en)	2001-05-26
DE60003509T2 (de)	2004-04-15
JP4260354B2 (ja)	2009-04-30
ES2177373B1 (es)	2003-11-01
DE60027919D1 (de)	2006-06-14
PL195910B1 (pl)	2007-11-30
ATE243704T1 (de)	2003-07-15
TR200003474A2 (tr)	2001-07-23
PL344101A1 (en)	2001-06-04
EP1103558A2 (de)	2001-05-30
EP1234833B1 (de)	2006-05-10
TR200003474A3 (tr)	2001-07-23
DE60003509D1 (de)	2003-07-31
CA2326930C (en)	2005-03-22
ATE325805T1 (de)	2006-06-15
ES2207403A1 (es)	2004-05-16
EP1103558A3 (de)	2001-07-04
EP1234833A2 (de)	2002-08-28
ES2207403B1 (es)	2005-03-01
JP2009007376A (ja)	2009-01-15
JP2001187797A (ja)	2001-07-10
US6451990B1 (en)	2002-09-17
EP1103558B1 (de)	2003-06-25

Legal Events

Date	Code	Title	Description
2002-07-13	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2002-08-28	AC	Divisional application: reference to earlier application	Ref document number: 1103558 Country of ref document: EP
2002-08-28	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2002-08-28	AX	Request for extension of the european patent	Free format text: AL;LT;LV;MK;RO;SI
2003-01-24	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2003-03-12	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2003-03-12	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2003-05-07	17P	Request for examination filed	Effective date: 20030121
2003-07-23	R17P	Request for examination filed (corrected)	Effective date: 20030221
2003-12-03	AKX	Designation fees paid	Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2003-12-17	RIN1	Information on inventor provided before grant (corrected)	Inventor name: FERNANDEZ MARI, FELIX Inventor name: LLORENTE GARCIA, ISIDRO Inventor name: BAYOD JASANADA, MIGUEL SANTOS
2005-08-10	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2005-11-05	GRAS	Grant fee paid	Free format text: ORIGINAL CODE: EPIDOSNIGR3
2006-03-24	GRAA	(expected) grant	Free format text: ORIGINAL CODE: 0009210
2006-05-10	AC	Divisional application: reference to earlier application	Ref document number: 1103558 Country of ref document: EP Kind code of ref document: P
2006-05-10	AK	Designated contracting states	Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
2006-05-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20060510 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060510 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060510 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060510 Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060510 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060510 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060510
2006-05-10	REG	Reference to a national code	Ref country code: GB Ref legal event code: FG4D
2006-05-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: EP
2006-06-14	REF	Corresponds to:	Ref document number: 60027919 Country of ref document: DE Date of ref document: 20060614 Kind code of ref document: P
2006-06-14	REG	Reference to a national code	Ref country code: IE Ref legal event code: FG4D
2006-08-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060810 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060810
2006-08-11	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: DE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060811
2006-08-21	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060821
2006-10-10	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20061010
2006-11-01	NLV1	Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
2006-11-15	REG	Reference to a national code	Ref country code: CH Ref legal event code: PL
2007-02-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070228
2007-03-16	PLBE	No opposition filed within time limit	Free format text: ORIGINAL CODE: 0009261
2007-03-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT
2007-04-18	26N	No opposition filed	Effective date: 20070213
2007-05-04	EN	Fr: translation not filed
2007-10-24	GBPC	Gb: european patent ceased through non-payment of renewal fee	Effective date: 20070223
2008-01-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070223
2008-04-30	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20070309 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070223 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060811
2008-11-28	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: FR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060510
2009-08-31	PG25	Lapsed in a contracting state [announced via postgrant information from national office to epo]	Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20070223 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20060510

Publication	Publication Date	Title
EP1103558A3 (de)	2001-07-04	Herstellung von nicht-kristallinen und kristallinen Dihydratformen von Azithromycin
GB8823567D0 (en)	1988-11-16	4h-1-benzopyran-4-one derivative/its salt & process for producing same
NZ238340A (en)	1994-06-27	Preparation of 3-(methylamino)-piperidine derivatives
EP1418174A3 (de)	2004-06-23	Amorph ritonavir
EP1199018A3 (de)	2003-10-22	Warmhaltegerät für Nahrungsmittel mit einem verriegelbaren Drehdeckel
AU2491395A (en)	1996-01-25	New benzothiadiazine compound, process for its preparation and the pharmaceutical compositions which contain it
GR3018227T3 (en)	1996-02-29	Process for the preparation of 3-benzoyl-benzofuran derivatives.
CA2163274A1 (en)	1992-08-28	Intermediates for producing neuroleptic perhydro-1h-pyrido¬1,2-a\| pyrazines
PL308635A1 (en)	1995-11-27	Glucopyranosidic derivatives of bezothiophenols, pharmaceutical compositions containing them and method of obtaining such derivatives
CA2485433A1 (en)	2001-05-26	Preparation of non-crystalline and crystalline dihydrate forms of azithromycin
AU7224796A (en)	1997-04-30	New crystalline form of morphine-6-glucuronide
HUT56375A (en)	1991-08-28	Process for producing crystalline acid-addition salts of cefem carboxylic acid
GR3032427T3 (en)	2000-05-31	An improved process for preparing side chain derivatives of cyclohexapeptidyl lipopeptides
FR2669528B1 (fr)	1993-02-05	Implant destine a l'osteosynthese des fractures de l'extremite superieure de l'humerus.
WO2001077134A3 (en)	2002-08-08	Process for the preparation of 6-o-propargyl erythromycin derivatives
HUP0201301A3 (en)	2002-10-28	Polymorphs of a crystalline azabicyclo(2,2,2)octan-3-amine citrate and their pharmaceutical compositions and process for preparation of the compounds
AU2002367110A1 (en)	2003-07-15	Amorphous substance of tricyclic triazolobenzazepine derivative
EP1210911A3 (de)	2005-06-29	Knochenmarkbiopsienadel
PT828749E (pt)	2003-11-28	Composicoes e metodos para a sintese de derivados de organofosforo
Abdel-Fattah et al.	1991	Thermal behavior and structural variations of both chemically precipitated and biological hydroxyapatites
Amatuni et al.	1994	Diamond synthesis possibility investigation using CO {sub 2} laser radiation; Issledovanie vozmozhnosti sinteza almaza s ispolzovaniem izlucheniya CO {sub 2} lazera
AU1149800A (en)	2000-03-27	11beta-fluoro- 7alpha-(14, 14,15,15,15- pentafluoro-6- methyl-10-thia- 6-azapentadecyl) estra-1,3,5(10)- triene-3, 17beta-diol as a crystalline solvate
Amatuni et al.	1994	Diamond synthesis possibility investigation using CO2 laser radiation
NZ323964A (en)	2000-01-28	4,10beta-diacetoxy-2alpha-benzoyloxy-5beta,20-epoxy-1-hydroxy-9-oxo-19-nor-cy clopropa[g]tax-11-ene-13alpha-yl
Samojlov et al.	2000	On change of differential energy spectra of atoms sputtered from the Ni grain (111) surface at magnetic phase transformation; Ob izmenenii differentsial'nykh ehnergospektrov atomov, raspylennykh s poverkhnosti grani (111) Ni, pri magnitnom fazovom perekhode